Zytiga Pre-chemo Data Impress At ASCO, But Early Trial Termination Could Be An Issue
20:03 EDT 2 Jun 2012 | Elsevier Business Intelligence
Data from a Phase III trial of Johnson & Johnson’s blockbuster prostate cancer drug Zytiga, which was halted for efficacy in March, were released June 2 at ASCO, but at least one expert in the field questions whether the risk to the eventual cl..
Original Article: Zytiga Pre-chemo Data Impress At ASCO, But Early Trial Termination Could Be An Issue
More From BioPortfolio on "Zytiga Pre-chemo Data Impress At ASCO, But Early Trial Termination Could Be An Issue"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
